Eplin-alpha expression in human breast cancer, the impact on cellular migration and clinical outcome

Jiang, Wen Guo ORCID: https://orcid.org/0000-0002-3283-1111, Martin, Tracey Amanda ORCID: https://orcid.org/0000-0003-2690-4908, Lewis-Russell, Jonathan M., Douglas-Jones, Anthony Gordon, Ye, Lin ORCID: https://orcid.org/0000-0002-0303-2409 and Mansel, Robert Edward ORCID: https://orcid.org/0000-0002-8051-0726 2008. Eplin-alpha expression in human breast cancer, the impact on cellular migration and clinical outcome. Molecular Cancer 7 , 71. 10.1186/1476-4598-7-71

Preview

PDF - Published Version Available under License Creative Commons Attribution. Download (2MB) | Preview

Abstract

Introduction: To investigate the expression of EPLIN-α, epithelial protein lost in neoplasm, in human breast cancer tissues/cells and investigate the cellular impact of EPLIN-α on breast cancer cells. Experimental design: EPLIN-α was determined in tumour (n = 120) and normal mammary tissues (n = 32), and cancer cell lines (n = 16). Cell invasion, in vitro and in vivo growth of cells transfected with EPLIN-α were evaluated using in vitro invasion assay, in vitro and in vivo tumour model. Cellular migration was analysed using Electric Cell Impedance Sensing assays. Results: Low level of EPLIN-α was seen in tumour tissues. Grade-2/3 tumours had significantly lower levels of EPLIN-α compared with grade-1 (p = 0.047 and p = 0.046 vs grade-1, respectively). Patients with poor prognosis had a significantly lower levels of EPLIN-α compared with those with good prognosis (p = 0.0081). Patients who developed recurrence and died of breast cancer had significantly lower levels of EPLIN-α compared with those who remained disease free (p = 0.0003 and p = 0.0008, respectively) (median follow-up 10 years). Patients with high levels of EPLIN-α transcript had a longer survival than those with low levels. Over-expression of EPLIN-α in breast cancer cells by way of transfection rendered cells less invasive, less motile and growing at a slower pace in vitro and in vivo. An ERK inhibitor was shown to be able to abolish the effect of EPLIN expression. Conclusion: It is concluded that expression of EPLIN-α in breast cancer is down-regulated in breast cancer cells and tissues, a change linked to the prognosis. EPLIN-α acts as a potential tumour suppressor by inhibition of growth and migration of cancer cells.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Publisher:	BioMed Central
ISSN:	1476-4598
Date of First Compliant Deposit:	30 March 2016
Last Modified:	01 Jun 2023 19:02
URI:	https://orca.cardiff.ac.uk/id/eprint/28779

Citation Data

Cited 94 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item